Robert Lisicki
Chief Executive Officer at ZURA BIO LIMITED
Net worth: - $ as of 29/04/2024
Robert Lisicki active positions
Companies | Position | Start | End |
---|---|---|---|
CADRENAL THERAPEUTICS, INC. | Director/Board Member | 22/07/2023 | - |
ZURA BIO LIMITED | Director/Board Member | 07/04/2024 | - |
Chief Executive Officer | 07/04/2024 | - | |
Chief Operating Officer | 07/01/2024 | 07/04/2024 | |
President | 07/01/2024 | 07/04/2024 | |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Director/Board Member | 11/10/2023 | - |
Career history of Robert Lisicki
Former positions of Robert Lisicki
Companies | Position | Start | End |
---|---|---|---|
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Director/Board Member | 30/09/2022 | 28/02/2023 |
Chief Executive Officer | 30/09/2022 | 28/02/2023 | |
ARENA PHARMACEUTICALS | Corporate Officer/Principal | 25/11/2018 | 28/02/2022 |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Sales & Marketing | 31/07/2014 | 31/03/2018 |
AMGEN INC. | Corporate Officer/Principal | - | - |
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Training of Robert Lisicki
State University of New York at Albany | Undergraduate Degree |
Statistics
International
United States | 10 |
Operational
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Sectoral
Health Technology | 9 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
AMGEN INC. | Health Technology |
CADRENAL THERAPEUTICS, INC. | Health Technology |
ZURA BIO LIMITED | Health Technology |
Private companies | 4 |
---|---|
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Health Technology |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Health Technology |
- Stock Market
- Insiders
- Robert Lisicki
- Experience